ADAR1 Capital Management LLC Has $3.77 Million Stock Holdings in Savara Inc. $SVRA

Key Points

• ADAR1 Capital Management LLC increased its stake in Savara Inc. by 37.6%, owning 1,360,291 shares valued at approximately $3.77 million, according to its recent SEC filing.
• Multiple institutional investors have also raised their positions in Savara, with Frazier Life Sciences Management increasing by 32.4% to hold about 11.46 million shares valued at $31.75 million.
• Savara's stock has seen a slight increase of 0.3%, currently trading at $3.28, with analysts predicting an average target price of $6.17 and a consensus rating of "Moderate Buy."

ADAR1 Capital Management LLC grew its holdings in Savara Inc. (NASDAQ:SVRA - Free Report) by 37.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,360,291 shares of the company's stock after acquiring an additional 371,823 shares during the period. ADAR1 Capital Management LLC owned 0.79% of Savara worth $3,768,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in SVRA. Frazier Life Sciences Management L.P. grew its position in Savara by 32.4% in the first quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company's stock worth $31,751,000 after acquiring an additional 2,801,922 shares in the last quarter. Vestal Point Capital LP grew its position in Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company's stock worth $33,079,000 after acquiring an additional 2,685,000 shares in the last quarter. Farallon Capital Management LLC grew its position in Savara by 49.9% in the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock worth $20,983,000 after acquiring an additional 2,275,000 shares in the last quarter. Deerfield Management Company L.P. Series C grew its position in Savara by 23.2% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock worth $24,449,000 after acquiring an additional 1,498,223 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in Savara by 32.5% in the first quarter. Emerald Advisers LLC now owns 3,090,213 shares of the company's stock worth $8,560,000 after acquiring an additional 757,533 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Insider Activity

In other Savara news, Director Richard J. Hawkins acquired 48,225 shares of the company's stock in a transaction dated Friday, June 20th. The stock was bought at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director owned 115,466 shares in the company, valued at $235,550.64. This represents a 71.72% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.33% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on SVRA. Wells Fargo & Company decreased their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, May 28th. Oppenheimer upped their price objective on shares of Savara from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, August 15th. HC Wainwright upped their price objective on shares of Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday. Guggenheim reaffirmed a "buy" rating and set a $8.00 price objective (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. Finally, Evercore ISI decreased their price objective on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Wednesday, May 28th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $6.67.

Savara Stock Performance

Savara stock traded up $0.16 during mid-day trading on Thursday, reaching $3.58. The company had a trading volume of 1,775,465 shares, compared to its average volume of 1,613,274. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $4.70. The company has a 50 day moving average of $2.68 and a 200-day moving average of $2.70. The firm has a market cap of $618.77 million, a price-to-earnings ratio of -7.16 and a beta of 0.56.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). On average, sell-side analysts expect that Savara Inc. will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.